Analysts hold a pessimistic view on Enanta Pharmaceuticals after its earnings shortfall. The consensus price target dropped significantly, suggesting lower earnings per share are a key indicator for the company's valuation. The company's long-term prospects are deemed more crucial than next year's earnings.
The low P/S ratio of Enanta Pharmaceuticals may be justified by its declining revenue and poor growth outlook compared to the industry. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.
Recent insider sale at Enanta Pharmaceuticals reflects possible contentment with lower company valuation. The absence of insider buying over past year raises caution for potential investors.
Upgrades •$A.O.史密斯(AOS.US)$: Longbow Research Upgrades to Buy from Neutral - PT $71 •$Callon Petroleum(CPE.US)$: RBC Upgrades to Outperform from Sector Perform - PT $75 •$鄧白氏(DNB.US)$: BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16) •$Enanta Pharmaceuticals(ENTA.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39) •$康寧(GLW.US)$: CFRA Upgrades to Strong Buy ...
Gainers: •$Rocket Pharmaceuticals(RCKT.US)$+10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy) •$加拿大鵝(GOOS.US)$+9.4% (the company reported an unexpected profit as well as better-than-expected revenue) •$SIGA Technologies(SIGA.US)$+6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
Enanta Pharmaceuticals股票討論區
專欄Top upgrades and downgrades on 7/6: MRK, EOG, ABT, UNP and more
• $A.O.史密斯(AOS.US)$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum(CPE.US)$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $鄧白氏(DNB.US)$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
•$Enanta Pharmaceuticals(ENTA.US)$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $康寧(GLW.US)$ : CFRA Upgrades to Strong Buy ...
專欄Today's pre-market stock movers: BBIO, LZB, ORA, DOW and more
• $La-Z-Boy(LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $輝瑞(PFE.US)$)
• $Ikena Oncology(IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
專欄Today's pre-market stock movers: CRM, WB, LI, NIO and more
• $維多利亞的秘密(VSCO.US)$ +10.4% (In reaction to earnings)
• $賽富時(CRM.US)$ +9.0% (In reaction to earnings)
• $Navigator(NVGS.US)$ +4.9% (names Mads Peter Zacho as CEO)
• $微博(WB.US)$ +4.7% (In reaction to earnings)
• $CAE Inc(CAE.US)$ +4.7% (In reaction to earnings)
• $Laredo Petroleum(LPI.US)$ +4% (authorized $200 mln share repurchase program)
• $Axsome Therapeutics(AXSM.US)$ +3.1% (Late-Breaking Presentations of P...
專欄Top upgrades and downgrades on 6/1
• $Blueprint Medicines(BPMC.US)$ : Jefferies Upgrades to Buy from Hold - PT $78 (from $88)
• $CatchMark Timber Trust Inc(CTT.US)$ : Raymond James Upgrades to Market Perform from Underperform
• $丹納赫(DHR.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $310 (from $299)
• $Enanta Pharmaceuticals(ENTA.US)$ : Evercore ISI Upgrades to In Line from Underperform - PT $39 (from $35)
• $FEMSA(FMX.US)$ : Bradesco BBI Upgrades to Outperform f...
專欄Today's pre-market stock movers: GOOS, TSLA, KSS, UAA and more
• $Rocket Pharmaceuticals(RCKT.US)$ +10.5% (Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy)
• $加拿大鵝(GOOS.US)$ +9.4% (the company reported an unexpected profit as well as better-than-expected revenue)
• $SIGA Technologies(SIGA.US)$ +6.4% (FDA approves Intravenous (IV) Formulation of TPOXX (tecovirimat) for t...
暫無評論